PRF Technologies Ltd. (PRFX)
NASDAQ: PRFX · Real-Time Price · USD
1.360
0.00 (0.00%)
At close: Jul 2, 2026, 4:00 PM EDT
1.399
+0.039 (2.90%)
After-hours: Jul 2, 2026, 7:58 PM EDT
PRF Technologies Revenue
In the year 2025, PRF Technologies had annual revenue of $17.00K. PRF Technologies had revenue of $17.00K in the half year ending December 31, 2025.
Revenue (ttm)
$17.00K
Revenue Growth
n/a
P/S Ratio
243.35
Revenue / Employee
$2,429
Employees
7
Market Cap
4.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 43.20M |
| Sunshine Biopharma | 35.49M |
| cbdMD | 19.98M |
| Sonoma Pharmaceuticals | 19.53M |
| Universe Pharmaceuticals INC | 17.86M |
| InMed Pharmaceuticals | 4.94M |
| RedHill Biopharma | 286.00K |
| Gelteq | 270.85K |
PRFX News
- 7 days ago - PRF Technologies announces expanded results from PRF-110 study - TheFly
- 7 days ago - PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark - GlobeNewsWire
- 10 days ago - PRF Technologies files to sell 7.5M ordinary shares for holders - TheFly
- 4 weeks ago - Why Is Penny Stock PRF Technologies (PRFX) Up Today? - TipRanks
- 5 weeks ago - PRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets - GlobeNewsWire
- 5 weeks ago - PRF Technologies announces results from study comparing PRF-110 to Zynrelef - TheFly
- 5 weeks ago - PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study - GlobeNewsWire
- 7 weeks ago - PRF Technologies registers to sell 3M ordinary shares for holders - TheFly